@Alfred Thank you. So is not a difference between Tysabri and Tyruko?
@Mandypar Yes, there is a difference between Tysabri and Tyruko. Tysabri is the brand name for the drug natalizumab, which is a humanized monoclonal antibody used to treat multiple sclerosis and Crohn's disease. Natalizumab works by blocking certain white blood cells from entering the brain or intestines, which helps to reduce inflammation in these areas. Tysabri is a branded biologic medication that has been on the market for a number of years and is manufactured by Biogen. On the other hand, Tyruko is a biosimilar to Tysabri. It contains the same active ingredient (natalizumab) as Tysabri but is produced by a different pharmaceutical company. Tyruko has demonstrated similarity in terms of safety, efficacy, and quality to Tysabri through the rigorous approval process required for biosimilars. Biosimilars like Tyruko are intended to provide more affordable treatment options while offering the same therapeutic benefits as the original branded biologic (Tysabri). In summary, Tysabri is the original branded biologic drug containing natalizumab, while Tyruko is a biosimilar version of Tysabri that has undergone a thorough evaluation process to demonstrate its similarity and effectiveness.
@Mandypar Certainly! A branded biologic medicine is an original biologic drug that has been developed by a pharmaceutical company. These medicines are protected by patents, which means that only the company that developed the drug can manufacture and sell it. Branded biologics are typically very expensive due to the high costs associated with research, development, and manufacturing. On the other hand, a biosimilar medicine is a biologic drug that is highly similar to an already approved branded biologic (also known as the reference product). Biosimilars are developed to be highly similar in terms of safety, efficacy, and quality to the reference product. However, they are not exact copies due to the complex nature of biologics. Biosimilars go through a rigorous approval process to demonstrate their similarity to the reference product and are generally more cost-effective than the original branded biologic. In summary, a branded biologic is the original version of a biologic drug developed by a pharmaceutical company, while a biosimilar is a highly similar version of a previously approved biologic that is typically more affordable.